EBIT SEK 12.9m (+24% vs. ABGSCe 10.4m) Q3 numbers imply EBIT upgrades of 4-3% Trading at 23x ’22e EV...
Exel’s Q3 results didn’t meet our estimates, but long-term EBIT potential remains significant even i...
Pihlajalinna’s Q3 revenue landed close to estimates, whereas profitability came in on the soft side.
Investment portfolio earnings the only disturbance… …in another solid quarter from BankNordik Mid-ra...
Eltel is likely to grow at high single-digit rates from here, but valuation already largely anticipa...
Sales in line with ABGSCe, EBIT beat by 20% Estimates raised for Q4, minor revisions for ‘23e & ‘24e...
Ascelia is reporting progress towards pivotal results with contained operational costs and cashflow.
Redeye is overall positive to the second interim analysis from Vicore’s phase II trial in IPF with d...
Redeye comments on Medivir's third quarter report. There have been some positive developments in fo...
The Q3 results showed relatively minor deviations from our estimates and IFPM fell 2% y/y.
Following BankNordik's Q3 report, we lift 2023E-24E adjusted EPS by ~11-15% to reflect a positive im...
Redeye saw a lower sales development than we expected, while Opex was lower than estimates.
Both NII and NCI came in slightly better than expected in Q3.
Taaleri announced today its new flagship fund, SolarWind III, in line with earlier communication.
Addvise, en nischförvärvare av medicintekniska bolag, har via förvärv och hög organisk tillväxt ökat...
Elanders står stadigt och redovisar ett starkt resultat för Q3.
Redeye provides its comments on Optomed’s Q3 2022 report.
Redeye comments on Active Biotech's report for the third quarter and discusses several near-term mil...
Med nio rapporterade månader i ryggen står det klart att Maven Wireless Sweden AB (”Maven” eller ”Bo...
Losses on bond portfolio behind net profit… … as indicated in net profit downgrade in October Core o...
